Skip to main content
SpringerLink
Log in

Iftikhar and Colleagues Reply: Methodology Clarified

  • LETTER TO THE EDITOR
  • Published:
Lung Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Iftikhar IH, Schimmel M, Bender W, Swenson C, Amrol D (2018) Comparative efficacy of anti IL-4, IL-5 and IL-13 drugs for treatment of eosinophilic asthma: a network meta-analysis. Lung 196:517–530

    Article  CAS  PubMed  Google Scholar 

  2. Chupp GL, Bradford ES, Albers FC, Bratton DJ, Wang-Jairaj J, Nelsen LM, Trevor JL, Magnan A, Ten Brinke A (2017) Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. Lancet Respir Med 5:390–400

    Article  PubMed  Google Scholar 

  3. Bel EH, Wenzel SE, Thompson PJ, Prazma CM, Keene ON, Yancey SW, Ortega HG, Pavord ID, Investigators S (2014) Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med 371:1189–1197

    Article  CAS  PubMed  Google Scholar 

  4. Castro M, Zangrilli J, Wechsler ME, Bateman ED, Brusselle GG, Bardin P, Murphy K, Maspero JF, O’Brien C, Korn S (2015) Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med 3:355–366

    Article  CAS  PubMed  Google Scholar 

  5. Nair P, Wenzel S, Rabe KF, Bourdin A, Lugogo NL, Kuna P, Barker P, Sproule S, Ponnarambil S, Goldman M et al (2017) Oral glucocorticoid-sparing effect of benralizumab in severe asthma. N Engl J Med 376:2448–2458

    Article  CAS  PubMed  Google Scholar 

  6. Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, Ortega H, Chanez P (2012) Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 380:651–659

    Article  CAS  PubMed  Google Scholar 

  7. Hanania NA, Korenblat P, Chapman KR, Bateman ED, Kopecky P, Paggiaro P, Yokoyama A, Olsson J, Gray S, Holweg CT et al (2016) Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials. Lancet Respir Med 4:781–796

    Article  CAS  PubMed  Google Scholar 

  8. Castro M, Corren J, Pavord ID, Maspero J, Wenzel S, Rabe KF, Busse WW, Ford L, Sher L, FitzGerald JM et al (2018) Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med 378:2486–2496

    Article  CAS  PubMed  Google Scholar 

  9. Rabe KF, Nair P, Brusselle G, Maspero JF, Castro M, Sher L, Zhu H, Hamilton JD, Swanson BN, Khan A et al (2018) Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med 378:2475–2485

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Pulmonary, Allergy, Critical Care & Sleep Medicine, Emory University School of Medicine, 613 Michael St, NE, Atlanta, GA, USA

    Imran H. Iftikhar, Mathew Schimmel, William Bender & Colin Swenson

  2. Division of Allergy and Immunology, University of South Carolina School of Medicine, Columbia, SC, USA

    David Amrol

Authors
  1. Imran H. Iftikhar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mathew Schimmel
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. William Bender
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Colin Swenson
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. David Amrol
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Imran H. Iftikhar.

Ethics declarations

Conflict of interest

The authors declare that they have no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Iftikhar, I.H., Schimmel, M., Bender, W. et al. Iftikhar and Colleagues Reply: Methodology Clarified. Lung 197, 107–109 (2019). https://doi.org/10.1007/s00408-018-0185-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00408-018-0185-8

Search

Navigation